Kenvue (NYSE:KVUE) Rating Increased to Strong-Buy at Rothschild Redb

Key Points

• Kenvue's stock rating was upgraded from "hold" to "strong-buy" by analysts at Rothschild Redb.
• The average rating for Kenvue is currently "Hold," with a consensus price target of $23.12.
• The company's latest quarterly earnings exceeded estimates, reporting $0.29 earnings per share, surpassing the consensus estimate of $0.28.

Kenvue (NYSE:KVUE - Get Free Report) was upgraded by stock analysts at Rothschild Redb from a "hold" rating to a "strong-buy" rating in a report released on Friday,Zacks.com reports.

KVUE has been the topic of several other research reports. Rothschild & Co Redburn raised Kenvue from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $22.50 to $22.00 in a research report on Friday. UBS Group lowered their price target on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research report on Thursday, July 17th. Bank of America lowered their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. Redburn Partners set a $22.00 price target on Kenvue in a research report on Friday. Finally, Canaccord Genuity Group lowered their price target on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kenvue presently has an average rating of "Hold" and a consensus price target of $23.12.

Kenvue Stock Up 1.4%

Shares of Kenvue stock opened at $16.40 on Friday. The business's 50 day simple moving average is $20.37 and its 200 day simple moving average is $21.83. Kenvue has a 52-week low of $16.07 and a 52-week high of $25.17. The firm has a market cap of $31.48 billion, a PE ratio of 22.17, a P/E/G ratio of 2.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business's quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KVUE. Pittenger & Anderson Inc. bought a new position in shares of Kenvue during the 1st quarter worth approximately $30,000. Trust Co. of Vermont boosted its stake in Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock valued at $33,000 after purchasing an additional 1,150 shares during the period. TruNorth Capital Management LLC bought a new stake in Kenvue in the 1st quarter valued at $36,000. Truvestments Capital LLC bought a new stake in Kenvue in the 1st quarter valued at $37,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its stake in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after purchasing an additional 1,287 shares during the period. 97.64% of the stock is currently owned by institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.